Loading
Life sciences · Journal article
Addictive Behaviors Reports · August 27, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a descriptive analysis of US drug overdose death trends from 2018 to 2024, showing that while overall opioid-driven overdose mortality declined 27.9% from 2022 peak to 2024, deaths involving stimulants (cocaine and methamphetamine) without opioids increased modestly (+1.7% and +2.4% respectively from 2023 to 2024). Increases were geographically and demographically heterogeneous, notably affecting White populations (cocaine) and Black, American Indian/Alaska Native, and older adults (methamphetamine).
Descriptive epidemiological analysis using joinpoint regression of aggregated national registry data. All unintentional drug overdose deaths in the United States from 2018 to 2024, stratified by race/ethnicity (White, Black, Hispanic, American Indian/Alaska Native), age group (including 55+), and US census region (Northeast, Midwest, and others).. United States; data analysed by US census region.
National DOD rates declined 27.9% from 2022 peak to 2024, driven by fentanyl-involved mortality reductions Cocaine-without-opioid DOD rates increased 1.7% from 2023 to 2024 Methamphetamine-without-opioid DOD rates increased 2.4% from 2023 to 2024
National DOD rates declined 27.9% from 2022 peak to 2024, driven by fentanyl-involved mortality reductions
Public health professionals and clinicians should recognize that opioid-focused harm reduction and overdose prevention efforts, while successful in reducing fentanyl-involved deaths, may not address rising stimulant-involved mortality. Prevention and treatment strategies targeting stimulant use disorder (cocaine and methamphetamine) without opioids warrant expansion, particularly in the Northeast and among historically underserved populations (AIAN, Black, and older adults).
Descriptive epidemiological analysis of aggregated mortality data showing temporal trends in stimulant-involved overdose deaths, without comparison group or causal inference; characterizes a public health pattern rather than evaluating an intervention or definitive outcome.
As stated by the source record.
Quoted from the source exactly as published.
Public health professionals and clinicians should recognize that opioid-focused harm reduction and overdose prevention efforts, while successful in reducing fentanyl-involved deaths, may not address rising stimulant-involved mortality. Prevention and treatment strategies targeting stimulant use disorder (cocaine and methamphetamine) without opioids warrant expansion, particularly in the Northeast and among historically underserved populations (AIAN, Black, and older adults).
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
After two decades of persistent growth, US drug overdose deaths (DODs) declined sharply in 2024, largely driven by reductions in fentanyl-involved mortality. However, trends in DODs involving stimulants without opioids remain less characterized and may follow distinct patterns. We analyzed aggregated data on unintentional DODs from 2018 to 2024 using the CDC data. Age-adjusted DOD rates were calculated using the 2000 US standard population. Joinpoint regression was used to identify significant temporal changes in mortality trends across substance categories. We examined percent changes in rates from 2023 to 2024 for cocaine and methamphetamine DODs without opioids, stratified by race/ethnicity, age group, and US census region. Nationally, DOD rates declined by 27.9% from their 2022 peak to 2024, paralleling reductions in fentanyl-involved deaths. In contrast, rates of DODs involving stimulants without opioids increased slightly (cocaine: +1.7%; methamphetamine: +2.4%) from 2023 to 2024. Increases were observed nationally among White populations for cocaine without opioids and among Black, American Indian/Alaska Native (AIAN), and 55+ populations for methamphetamine without opioids. The Northeast experienced the largest increases for stimulant-without-opioid deaths, while the Midwest showed pronounced racial/ethnic divergence, including increases among White populations but substantial declines among Hispanic populations. Methamphetamine-without-opioid DODs rose markedly among AIAN populations in some regions. These findings highlight an evolving overdose crisis and underscore the need for prevention strategies that extend beyond opioid-focused interventions to address stimulant-specific harms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.